Active Ingredient History

NOW
  • Now
Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations.   Wikipedia

4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline | bpi-2009 | icotinib | icotinib hydrochloride

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue